- Home
- GNLX vs PFO Comparison
GNLX vs PFO Comparison
Compare GNLX & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | PFO |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 117.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | PFO |
|---|---|---|
| Price | $2.57 | $9.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.80 | N/A |
| AVG Volume (30 Days) | ★ 151.5K | 33.9K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $8.01 |
| 52 Week High | $8.54 | $9.90 |
Technical Indicators
Market Signals| Indicator | GNLX | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 47.50 |
| Support Level | $2.54 | N/A |
| Resistance Level | $3.00 | $9.33 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.00 | 68.97 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.